NRXP
NRX Pharmaceuticals, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 2 ▼ NRx Pharmaceuticals announced an underwritten public offering of com…
- Jun 3 ▼ NRx Pharmaceuticals priced an underwritten public offering of 5,714,…
- Jun 4 ▼ NRx Pharmaceuticals closed an underwritten public offering of common…
- Jun 5 ▲ NRx Pharmaceuticals announced the presentation of a peer-reviewed po…
- Jul 22 ▲ NRX Pharmaceuticals' subsidiary NRX Defense Systems received a lette…
- Aug 7 ▲ NRx Pharmaceuticals disclosed that the FDA completed first-round rev…
- Aug 14 ▼ Short interest jumps 32.4% to 8.67M
- Aug 17 ▲ NRx Pharmaceuticals reported Q2 2026 financial results with a net lo…
- Oct 5 ▲ NRx Pharmaceuticals' subsidiary, NRx Defense Systems, was awarded an…
- Oct 30 ▲ NRx Pharmaceuticals announced FDA approval of its Abbreviated New Dr…
- Nov 2 ▲ NRx Pharmaceuticals announced FDA approval of its ANDA for Preservat…
- Nov 10 FDA decision: PDUFA: NRXP, NRX-100 in drug shortage product, 2026-11-10
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q3 2026: 13 added (0 new), 2 trimmed or exited.
- AnalystsBULLISH
10 of 11 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.080 → −$0.150 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +5.2% to 10.46M shares. 4.6 days to cover, ≈24.0% of shares.
- TrendDOWNTREND
23% below its 50-day average.
- SocialQUIET
Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MARSHALL WACE, LLP | DOUBLED | $2.9M |
| COMMONWEALTH EQUITY SERVICES, LLC | ADD | $1.7M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $1.3M |
| VANGUARD FIDUCIARY TRUST CO | ADD | $758.6K |
| MORGAN STANLEY | DOUBLED | $298.4K |
| JANE STREET GROUP, LLC | TRIM | $106.0K |
| Vanguard Global Advisers, LLC | DOUBLED | $50.2K |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $35.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
11 analystsPrice is below the lowest target. Median implies +2179%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 11, 2026 | BTIG MAINTAIN | Buy |
| Nov 2, 2026 | Ascendiant Capital MAINTAIN | Buy |
| Oct 1, 2026 | Ascendiant Capital MAINTAIN | Buy |
| Sep 14, 2026 | BTIG REITERATE | Buy |
| Aug 25, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 18, 2026 | BTIG REITERATE | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
ABRAMS MICHAEL S Chief Financial Officer Jul 28, 2026 | AWARD | 75,000 sh |
Javitt Jonathan C CEO and Chairman Jul 28, 2026 | AWARD | 150,000 sh |
Casper Joseph Michael Chief Operating Officer Jan 27, 2026 | AWARD | 100,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.15 | -$0.15–-$0.15 | +0.0% | $1.3M |
| Next Q | -$0.17 | -$0.17–-$0.17 | +0.0% | $2.6M |
| Current FY | -$0.80 | -$0.80–-$0.80 | +0.0% | $5.6M |
| Next FY | -$0.35 | -$0.35–-$0.35 | +0.0% | $77.5M |
Short side
FINRA· Oct 30, 2026SecBot reports
14 filings · 8 press releases · 7 bullish · 0 bearish · 7 neutral- NEUTRAL DEFA14ANov 5, 2026
NRX Pharmaceuticals filed additional definitive proxy soliciting materials (DEFA14A) on the same…
Monitor for additional proxy solicitation materials or a dissident filing (DFAN14A) that may detail the opposing candidate or proposals. The contested election introduces governance uncertainty but…
- NEUTRAL DEF 14ANov 5, 2026
NRX Pharmaceuticals filed its definitive proxy statement for the 2026 annual meeting, seeking to…
The DEFA14A filed concurrently signals a contested director election, which may lead to a proxy fight. Monitor for dissident filings and any shareholder proposals that could emerge before the…
- BULLISH 8-KNov 2, 2026
NRx Pharmaceuticals announced FDA approval of its ANDA for Preservative-Free Ketamine, ahead of…
Monitor the company's first commercial sales and revenue disclosures for Preservative-Free Ketamine in upcoming quarterly filings. The product addresses a known shortage, but the addressable market…
- BULLISH PRESS RELEASEOct 30, 2026
NRx Pharmaceuticals announced FDA approval of its Abbreviated New Drug Application (ANDA) for…
Monitor initial commercial uptake and revenue disclosures in upcoming quarterly filings. The company's transition from clinical-stage to commercial-stage with an approved product that addresses a…
All NRXP filing & press-release reports (22)
- DEFA14A reportNov 5, 2026
- DEF 14A reportNov 5, 2026
- 8-K reportNov 2, 2026
- PRESS-RELEASE reportOct 30, 2026
- 8-K reportOct 16, 2026
- 8-K reportOct 5, 2026
- 8-K reportSep 15, 2026
- 8-K reportSep 14, 2026
- 8-K reportAug 17, 2026
- PRESS-RELEASE reportAug 17, 2026
- 8-K reportAug 7, 2026
- 8-K reportJul 22, 2026
- PRESS-RELEASE reportJun 22, 2026
- PRESS-RELEASE reportJun 5, 2026
- PRESS-RELEASE reportJun 4, 2026
- PRESS-RELEASE reportJun 3, 2026
- PRESS-RELEASE reportJun 2, 2026
- PRESS-RELEASE reportMay 18, 2026
- PRESS-RELEASE reportMay 14, 2026
- PRESS-RELEASE reportMar 30, 2026
- PRESS-RELEASE reportMar 19, 2026
- DEFA14A reportFeb 24, 2026